A5054987615- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Hormonal and reproductive studies
- Sexual Differentiation and Disorders
- Prostate Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- Hormonal Regulation and Hypertension
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Cancer, Lipids, and Metabolism
- Metastasis and carcinoma case studies
- Breast Cancer Treatment Studies
- Multiple and Secondary Primary Cancers
- Urologic and reproductive health conditions
- Nutrition, Genetics, and Disease
- Heat shock proteins research
- Steroid Chemistry and Biochemistry
Massachusetts General Hospital
2021-2024
Harvard University
2023-2024
University of Hawaii Cancer Center
2023
Dana-Farber Cancer Institute
2022-2023
Icahn School of Medicine at Mount Sinai
2021
Cleveland Clinic
2016-2019
Cleveland Clinic Lerner College of Medicine
2016-2019
Memorial Sloan Kettering Cancer Center
2013
Glioblastoma is the most common and aggressive primary brain tumour. Standard of care consists surgical resection followed by radiotherapy concomitant maintenance temozolomide (temozolomide/radiotherapy→temozolomide). Corticosteroids are commonly used perioperatively to control cerebral oedema frequently continued throughout subsequent treatment, notably radiotherapy, for amelioration side effects. The effects corticosteroids such as dexamethasone on cell growth in glioma models patient...
Jupyter Notebooks have transformed the communication of data analysis pipelines by facilitating a modular structure that brings together code, markdown text, and interactive visualizations. Here, we extended to broaden their accessibility with Appyters. Appyters turn into fully functional standalone web-based bioinformatics applications. present users an entry form enabling them upload set various parameters for multitude workflows. Once is filled, Appyter executes corresponding notebook in...
Abstract Aberrant estrogen receptor (ER) signaling is central to the pathogenesis of many breast cancers. Like ER, androgen (AR) a steroid nuclear that frequently expressed in cancer and has long been considered an attractive therapeutic target. Although androgens were historically employed treatment cancer, this strategy largely fallen out favor with advent modern anti-estrogens, due virilizing effects from androgens, as well concerns could be converted estrogens fuel tumor growth. Recent...
Abstract Purpose: Steroidogenic enzymes are essential for prostate cancer development. Enzymes inactivating potent androgens were not investigated thoroughly, which leads to limited interference strategies therapy. Here we characterized the clinical relevance, significance, and regulation mechanism of enzyme HSD17B2 in Experimental Design: expression was detected with patient specimens cell lines. Function steroidogenesis, androgen receptor (AR) signaling, tumor growth lines a xenograft...
No AccessJournal of UrologyAdult Urology1 Sep 2017Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance Yaw A. Nyame, Nima Almassi, Samuel C. Haywood, Daniel J. Greene, Vishnu Ganesan, Charles Dai, Joseph Zabell, Chad Reichard, Hans Arora, Anna Zampini, Alice Crane, Hettel, Ahmed Elshafei, Khaled Fareed, Robert Stein, Ryan K. Berglund, Michael Gong, Stephen Jones, Eric Klein, Andrew Stephenson NyameYaw Nyame ,...
Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5α-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, metabolic pathway DHT has not been rigorously investigated setting primary disease prostate.Experimental Design:...
As the continuation beyond progression (BP) of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is becoming increasingly attractive for treatment patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC), definition resistance factors crucial. The aim study was to investigate impact CDK 4/6i BP and explore potential genomic stratification factors.
Tissue-agnostic indications for targeted therapies have expanded options patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab TRK inhibitors larotrectinib entrectinib provide rationale next-generation sequencing (NGS) in effectively all tumor given potential clinical responses even otherwise refractory disease. As proof concept, this case report describes a 64-year-old woman triple-negative breast cancer to...
Introduction Estrogen receptor positive (ER+) breast cancer is the most common subtype, and therapeutic management relies primarily on inhibiting ER signaling. In metastatic setting, signaling typically targeted by selective estrogen degraders (SERDs) or aromatase inhibitors (AIs), latter of which prevent production. Activating ESR1 mutations are among emergent confer resistance to AIs.
Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer ctDNA testing assess genomic among ILC, ductal (IDC), and mixed histology.We retrospectively 980 clinically annotated (121 792 IDC, 67 histology) from three academic centers evaluation by Guardant360™. Single nucleotide variations (SNVs), copy number (CNVs), oncogenic pathways were compared across histologies.ILC...
Abstract Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice. Methods The study analyzed a multi-institutional cohort comprising 703 patients with luminal-like MBC characterized circulating tumor DNA through next generation sequencing (NGS). Pathway classification was defined based on previous...
We determined the effect of 5α-reductase inhibitors on disease reclassification in men with prostate cancer optimally selected for active surveillance.In this retrospective review we identified 635 patients surveillance between 2002 and 2015. Patients favorable features repeat biopsy, defined as absent Gleason upgrading, were included cohort. stratified by those who did or not receive finasteride dutasteride within 1 year diagnosis. The primary end point was grade reclassification, any...
Abstract Background: ESR1 hotspot mutations (HS) (i.e. 380, 536, 537, and 538) are important drivers of resistance to aromatase inhibitors, but the differential impact genomic variants (HS vs non-HS) on response endocrine therapies (ET) under clinical development, such as novel oral Selective Estrogen Receptor Degraders Modulators (SERDs SERMs), is not known. The aim study was evaluate non-HS pharmacodynamics SERDs SERMs an additional ET mechanism. Materials Methods: analyzed a...
About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with cancer, genetic alterations circulating tumor DNA (ctDNA) have not been well described.We retrospectively analyzed 749 metastatic cancer (MBC) ctDNA evaluation by Guardant360 three academic medical centers. Tumors were classified HER2-low, HER2-0 (IHC 0) or HER2-positive....
Abstract Background: MBC is usually classified based on ER and HER2 status. Although the absence of PR expression commonly associated with a poorer response to endocrine therapy (ET) an unfavorable prognosis, data regarding underlining molecular features that occur in this subgroup are still unclear. The aim study was investigate genomic differences between ER/PRpos HER2neg (PRpos) ERpos PR/HER2neg (PRneg) through circulating tumor DNA (ctDNA) profiling large multicenter consortium. Methods:...
Abstract Background: Despite how commonly synonymous mutations (SYN) and unknown significance (VUS) are detected in tissue circulating tumor DNA (ctDNA) next-generation sequencing (NGS), the potential for these somatic changes to impact personalized approaches metastatic breast cancer (MBC) is unclear. Emerging evidence suggests that SYN may play a role biology through mRNA stability, splicing, gene expression. The aim of this study was characterize VUS large multicenter consortium analyze...
Abstract Background: The use of circulating tumor (ct) DNA testing allows to detect resistant and actionable somatic alterations it could be associated with the incidental identification germline mutations. An univocal variant allele frequency (VAF) threshold distinguish germinal form mutations has not been assessed yet. We aimed correlate BRCA1/2 ctdNA detected mutational status determine potential VAF cutoff. Materials methods:We retrospectively analyzed incidence both (s) (g) in a...
Abstract Background: Alterations in the SPEN gene are rare primary breast cancer (~3%, ref: TCGA). is a hormone-inducible transcriptional repressor with known functions orchestrating X-inactivation females. Additionally, has been implicated as potential estrogen receptor co-repressor and molecular partner of NCOR2 well epigenetic modifiers such KMT2D HDACs via C-terminal interactions. loss-of-function associated tamoxifen resistance preclinical models. However, landscape alterations advanced...
Abstract Background: Limited data are available to determine the best therapeutic strategy for hormone-receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer (ABC) after progression on cyclin dependent kinase 4/6 inhibitors (CDK4/6i). The aim of this study was characterize genomic and prognostic profile patients (pts) that experienced disease first-line therapy with a CDK4/6i. Methods: retrospectively analyzed multi-institutional cohort 75 HR+/HER2- ABC experiencing endocrine...